APO Research
Talk to an analyst

APO RESEARCH · REPORT

Passive Immunizing Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Passive Immunizing Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025191 pages

Choose your research edition.

Industry ResearchPassive Immunizing Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Passive Immunizing Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Passive Immunizing Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Passive Immunizing Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Passive Immunizing Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Passive Immunizing Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Passive Immunizing Drugs include Xingmeng Biopharmaceuticals (Suzhou), Wuhan Institute of Biological Products, Sichuan Yuanda Shuyang Pharmaceutical, Shanxi Kangbao Biological Product, Sharon Bio-Medicine, Hualan Biological Engineering, North China Pharmaceutical, Sinopharm Group and Zydus Lifesciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Passive Immunizing Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Passive Immunizing Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Passive Immunizing Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Passive Immunizing Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Passive Immunizing Drugs Segment by Company

Xingmeng Biopharmaceuticals (Suzhou)

Wuhan Institute of Biological Products

Sichuan Yuanda Shuyang Pharmaceutical

Shanxi Kangbao Biological Product

Sharon Bio-Medicine

Hualan Biological Engineering

North China Pharmaceutical

Sinopharm Group

Zydus Lifesciences

Serum Institute of India

Sanofi Pasteur

Kedrion Biopharma

Kamada

Haffkine Bio-Pharmaceutical

Grifols

Bharat Biotech

Passive Immunizing Drugs Segment by Type

Rabies Immunoglobulin

Rabies Virus Monoclonal Antibody

Anti-rabies Serum

Passive Immunizing Drugs Segment by Application

Category II Exposure

Category III Exposure

Passive Immunizing Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Passive Immunizing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Passive Immunizing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Passive Immunizing Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Passive Immunizing Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Passive Immunizing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Passive Immunizing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Passive Immunizing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Passive Immunizing Drugs Industry Trends Table 2. Passive Immunizing Drugs Industry Drivers Table 3. Passive Immunizing Drugs Industry Opportunities and Challenges Table 4. Passive Immunizing Drugs Industry Restraints Table 5. Global Passive Immunizing Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Passive Immunizing Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Passive Immunizing Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Passive Immunizing Drugs Sales Market Share by Manufacturers Table 9. Global Passive Immunizing Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Passive Immunizing Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Passive Immunizing Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Passive Immunizing Drugs Manufacturers, Product Type & Application Table 13. Global Passive Immunizing Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Passive Immunizing Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rabies Immunoglobulin Table 17. Major Manufacturers of Rabies Virus Monoclonal Antibody Table 18. Major Manufacturers of Anti-rabies Serum Table 19. Global Passive Immunizing Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Passive Immunizing Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Passive Immunizing Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Passive Immunizing Drugs Sales Market Share by Type (2021-2026) Table 23. Global Passive Immunizing Drugs Sales Market Share by Type (2027-2032) Table 24. Global Passive Immunizing Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Passive Immunizing Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Passive Immunizing Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Passive Immunizing Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Passive Immunizing Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Category II Exposure Table 30. Major Manufacturers of Category III Exposure Table 31. Global Passive Immunizing Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Passive Immunizing Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global Passive Immunizing Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global Passive Immunizing Drugs Sales Market Share by Application (2021-2026) Table 35. Global Passive Immunizing Drugs Sales Market Share by Application (2027-2032) Table 36. Global Passive Immunizing Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Passive Immunizing Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global Passive Immunizing Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global Passive Immunizing Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Passive Immunizing Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Passive Immunizing Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Passive Immunizing Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Passive Immunizing Drugs Sales Market Share by Region (2021-2026) Table 44. Global Passive Immunizing Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Passive Immunizing Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Passive Immunizing Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America Passive Immunizing Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Passive Immunizing Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe Passive Immunizing Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Passive Immunizing Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Passive Immunizing Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Passive Immunizing Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Passive Immunizing Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global Passive Immunizing Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Passive Immunizing Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Passive Immunizing Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Passive Immunizing Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Passive Immunizing Drugs Revenue Market Share by Region (2027-2032) Table 63. Xingmeng Biopharmaceuticals (Suzhou) Company Information Table 64. Xingmeng Biopharmaceuticals (Suzhou) Business Overview Table 65. Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio Table 67. Xingmeng Biopharmaceuticals (Suzhou) Recent Development Table 68. Wuhan Institute of Biological Products Company Information Table 69. Wuhan Institute of Biological Products Business Overview Table 70. Wuhan Institute of Biological Products Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio Table 72. Wuhan Institute of Biological Products Recent Development Table 73. Sichuan Yuanda Shuyang Pharmaceutical Company Information Table 74. Sichuan Yuanda Shuyang Pharmaceutical Business Overview Table 75. Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 77. Sichuan Yuanda Shuyang Pharmaceutical Recent Development Table 78. Shanxi Kangbao Biological Product Company Information Table 79. Shanxi Kangbao Biological Product Business Overview Table 80. Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio Table 82. Shanxi Kangbao Biological Product Recent Development Table 83. Sharon Bio-Medicine Company Information Table 84. Sharon Bio-Medicine Business Overview Table 85. Sharon Bio-Medicine Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio Table 87. Sharon Bio-Medicine Recent Development Table 88. Hualan Biological Engineering Company Information Table 89. Hualan Biological Engineering Business Overview Table 90. Hualan Biological Engineering Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio Table 92. Hualan Biological Engineering Recent Development Table 93. North China Pharmaceutical Company Information Table 94. North China Pharmaceutical Business Overview Table 95. North China Pharmaceutical Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. North China Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 97. North China Pharmaceutical Recent Development Table 98. Sinopharm Group Company Information Table 99. Sinopharm Group Business Overview Table 100. Sinopharm Group Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sinopharm Group Passive Immunizing Drugs Product Portfolio Table 102. Sinopharm Group Recent Development Table 103. Zydus Lifesciences Company Information Table 104. Zydus Lifesciences Business Overview Table 105. Zydus Lifesciences Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Zydus Lifesciences Passive Immunizing Drugs Product Portfolio Table 107. Zydus Lifesciences Recent Development Table 108. Serum Institute of India Company Information Table 109. Serum Institute of India Business Overview Table 110. Serum Institute of India Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Serum Institute of India Passive Immunizing Drugs Product Portfolio Table 112. Serum Institute of India Recent Development Table 113. Sanofi Pasteur Company Information Table 114. Sanofi Pasteur Business Overview Table 115. Sanofi Pasteur Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Sanofi Pasteur Passive Immunizing Drugs Product Portfolio Table 117. Sanofi Pasteur Recent Development Table 118. Kedrion Biopharma Company Information Table 119. Kedrion Biopharma Business Overview Table 120. Kedrion Biopharma Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Kedrion Biopharma Passive Immunizing Drugs Product Portfolio Table 122. Kedrion Biopharma Recent Development Table 123. Kamada Company Information Table 124. Kamada Business Overview Table 125. Kamada Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Kamada Passive Immunizing Drugs Product Portfolio Table 127. Kamada Recent Development Table 128. Haffkine Bio-Pharmaceutical Company Information Table 129. Haffkine Bio-Pharmaceutical Business Overview Table 130. Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 132. Haffkine Bio-Pharmaceutical Recent Development Table 133. Grifols Company Information Table 134. Grifols Business Overview Table 135. Grifols Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Grifols Passive Immunizing Drugs Product Portfolio Table 137. Grifols Recent Development Table 138. Bharat Biotech Company Information Table 139. Bharat Biotech Business Overview Table 140. Bharat Biotech Passive Immunizing Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Bharat Biotech Passive Immunizing Drugs Product Portfolio Table 142. Bharat Biotech Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Passive Immunizing Drugs Distributors List Table 146. Passive Immunizing Drugs Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Passive Immunizing Drugs Product Image Figure 2. Global Passive Immunizing Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Passive Immunizing Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Passive Immunizing Drugs Sales (2021-2032) & (K Units) Figure 5. Global Passive Immunizing Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Passive Immunizing Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rabies Immunoglobulin Image Figure 9. Rabies Virus Monoclonal Antibody Image Figure 10. Anti-rabies Serum Image Figure 11. Global Passive Immunizing Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Passive Immunizing Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Passive Immunizing Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Passive Immunizing Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Passive Immunizing Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Passive Immunizing Drugs Revenue Market Share by Type (2021-2032) Figure 17. Category II Exposure Image Figure 18. Category III Exposure Image Figure 19. Global Passive Immunizing Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Passive Immunizing Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Passive Immunizing Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Passive Immunizing Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Passive Immunizing Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Passive Immunizing Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Passive Immunizing Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Passive Immunizing Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Passive Immunizing Drugs Sales Market Share by Country (2021-2032) Figure 39. China Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Passive Immunizing Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Passive Immunizing Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Passive Immunizing Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Passive Immunizing Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Passive Immunizing Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Passive Immunizing Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Passive Immunizing Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Passive Immunizing Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Passive Immunizing Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Passive Immunizing Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Rabies Immunoglobulin
  • Rabies Virus Monoclonal Antibody
  • Anti-rabies Serum
Applications
  • Category II Exposure
  • Category III Exposure
Companies covered
  • Xingmeng Biopharmaceuticals (Suzhou)
  • Wuhan Institute of Biological Products
  • Sichuan Yuanda Shuyang Pharmaceutical
  • Shanxi Kangbao Biological Product
  • Sharon Bio-Medicine
  • Hualan Biological Engineering
  • North China Pharmaceutical
  • Sinopharm Group
  • Zydus Lifesciences
  • Serum Institute of India
  • Sanofi Pasteur
  • Kedrion Biopharma
  • Kamada
  • Haffkine Bio-Pharmaceutical
  • Grifols
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Passive Immunizing Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Passive Immunizing Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Passive Immunizing Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Passive Immunizing Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Passive Immunizing Drugs Market Dynamics
  1. 2.1 Passive Immunizing Drugs Industry Trends
  2. 2.2 Passive Immunizing Drugs Industry Drivers
  3. 2.3 Passive Immunizing Drugs Industry Opportunities and Challenges
  4. 2.4 Passive Immunizing Drugs Industry Restraints
3 Passive Immunizing Drugs Market by Manufacturers
  1. 3.1 Global Passive Immunizing Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Passive Immunizing Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Passive Immunizing Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Passive Immunizing Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Passive Immunizing Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Passive Immunizing Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Passive Immunizing Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Passive Immunizing Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Passive Immunizing Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Passive Immunizing Drugs Tier 1, Tier 2, and Tier 3
4 Passive Immunizing Drugs Market by Type
  1. 4.1 Passive Immunizing Drugs Type Introduction
  2. 4.1.1 Rabies Immunoglobulin
  3. 4.1.2 Rabies Virus Monoclonal Antibody
  4. 4.1.3 Anti-rabies Serum
  5. 4.2 Global Passive Immunizing Drugs Sales by Type
  6. 4.2.1 Global Passive Immunizing Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Passive Immunizing Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Passive Immunizing Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Passive Immunizing Drugs Revenue by Type
  10. 4.3.1 Global Passive Immunizing Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Passive Immunizing Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Passive Immunizing Drugs Revenue Market Share by Type (2021-2032)
5 Passive Immunizing Drugs Market by Application
  1. 5.1 Passive Immunizing Drugs Application Introduction
  2. 5.1.1 Category II Exposure
  3. 5.1.2 Category III Exposure
  4. 5.2 Global Passive Immunizing Drugs Sales by Application
  5. 5.2.1 Global Passive Immunizing Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Passive Immunizing Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Passive Immunizing Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Passive Immunizing Drugs Revenue by Application
  9. 5.3.1 Global Passive Immunizing Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Passive Immunizing Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Passive Immunizing Drugs Revenue Market Share by Application (2021-2032)
6 Global Passive Immunizing Drugs Sales by Region
  1. 6.1 Global Passive Immunizing Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Passive Immunizing Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Passive Immunizing Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Passive Immunizing Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Passive Immunizing Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Passive Immunizing Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Passive Immunizing Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Passive Immunizing Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Passive Immunizing Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Passive Immunizing Drugs Revenue by Region
  1. 7.1 Global Passive Immunizing Drugs Revenue by Region
  2. 7.1.1 Global Passive Immunizing Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Passive Immunizing Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Passive Immunizing Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Passive Immunizing Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Passive Immunizing Drugs Revenue (2021-2032)
  8. 7.2.2 North America Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Passive Immunizing Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Passive Immunizing Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Passive Immunizing Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Passive Immunizing Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Xingmeng Biopharmaceuticals (Suzhou)
  2. 8.1.1 Xingmeng Biopharmaceuticals (Suzhou) Company Information
  3. 8.1.2 Xingmeng Biopharmaceuticals (Suzhou) Business Overview
  4. 8.1.3 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio
  6. 8.1.5 Xingmeng Biopharmaceuticals (Suzhou) Recent Developments
  7. 8.2 Wuhan Institute of Biological Products
  8. 8.2.1 Wuhan Institute of Biological Products Company Information
  9. 8.2.2 Wuhan Institute of Biological Products Business Overview
  10. 8.2.3 Wuhan Institute of Biological Products Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio
  12. 8.2.5 Wuhan Institute of Biological Products Recent Developments
  13. 8.3 Sichuan Yuanda Shuyang Pharmaceutical
  14. 8.3.1 Sichuan Yuanda Shuyang Pharmaceutical Company Information
  15. 8.3.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
  16. 8.3.3 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio
  18. 8.3.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments
  19. 8.4 Shanxi Kangbao Biological Product
  20. 8.4.1 Shanxi Kangbao Biological Product Company Information
  21. 8.4.2 Shanxi Kangbao Biological Product Business Overview
  22. 8.4.3 Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio
  24. 8.4.5 Shanxi Kangbao Biological Product Recent Developments
  25. 8.5 Sharon Bio-Medicine
  26. 8.5.1 Sharon Bio-Medicine Company Information
  27. 8.5.2 Sharon Bio-Medicine Business Overview
  28. 8.5.3 Sharon Bio-Medicine Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio
  30. 8.5.5 Sharon Bio-Medicine Recent Developments
  31. 8.6 Hualan Biological Engineering
  32. 8.6.1 Hualan Biological Engineering Company Information
  33. 8.6.2 Hualan Biological Engineering Business Overview
  34. 8.6.3 Hualan Biological Engineering Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio
  36. 8.6.5 Hualan Biological Engineering Recent Developments
  37. 8.7 North China Pharmaceutical
  38. 8.7.1 North China Pharmaceutical Company Information
  39. 8.7.2 North China Pharmaceutical Business Overview
  40. 8.7.3 North China Pharmaceutical Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 North China Pharmaceutical Passive Immunizing Drugs Product Portfolio
  42. 8.7.5 North China Pharmaceutical Recent Developments
  43. 8.8 Sinopharm Group
  44. 8.8.1 Sinopharm Group Company Information
  45. 8.8.2 Sinopharm Group Business Overview
  46. 8.8.3 Sinopharm Group Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sinopharm Group Passive Immunizing Drugs Product Portfolio
  48. 8.8.5 Sinopharm Group Recent Developments
  49. 8.9 Zydus Lifesciences
  50. 8.9.1 Zydus Lifesciences Company Information
  51. 8.9.2 Zydus Lifesciences Business Overview
  52. 8.9.3 Zydus Lifesciences Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Lifesciences Passive Immunizing Drugs Product Portfolio
  54. 8.9.5 Zydus Lifesciences Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Passive Immunizing Drugs Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 Sanofi Pasteur
  62. 8.11.1 Sanofi Pasteur Company Information
  63. 8.11.2 Sanofi Pasteur Business Overview
  64. 8.11.3 Sanofi Pasteur Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Pasteur Passive Immunizing Drugs Product Portfolio
  66. 8.11.5 Sanofi Pasteur Recent Developments
  67. 8.12 Kedrion Biopharma
  68. 8.12.1 Kedrion Biopharma Company Information
  69. 8.12.2 Kedrion Biopharma Business Overview
  70. 8.12.3 Kedrion Biopharma Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kedrion Biopharma Passive Immunizing Drugs Product Portfolio
  72. 8.12.5 Kedrion Biopharma Recent Developments
  73. 8.13 Kamada
  74. 8.13.1 Kamada Company Information
  75. 8.13.2 Kamada Business Overview
  76. 8.13.3 Kamada Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kamada Passive Immunizing Drugs Product Portfolio
  78. 8.13.5 Kamada Recent Developments
  79. 8.14 Haffkine Bio-Pharmaceutical
  80. 8.14.1 Haffkine Bio-Pharmaceutical Company Information
  81. 8.14.2 Haffkine Bio-Pharmaceutical Business Overview
  82. 8.14.3 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio
  84. 8.14.5 Haffkine Bio-Pharmaceutical Recent Developments
  85. 8.15 Grifols
  86. 8.15.1 Grifols Company Information
  87. 8.15.2 Grifols Business Overview
  88. 8.15.3 Grifols Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Grifols Passive Immunizing Drugs Product Portfolio
  90. 8.15.5 Grifols Recent Developments
  91. 8.16 Bharat Biotech
  92. 8.16.1 Bharat Biotech Company Information
  93. 8.16.2 Bharat Biotech Business Overview
  94. 8.16.3 Bharat Biotech Passive Immunizing Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bharat Biotech Passive Immunizing Drugs Product Portfolio
  96. 8.16.5 Bharat Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Passive Immunizing Drugs Value Chain Analysis
  2. 9.1.1 Passive Immunizing Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Passive Immunizing Drugs Production Mode & Process
  6. 9.2 Passive Immunizing Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Passive Immunizing Drugs Distributors
  9. 9.2.3 Passive Immunizing Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst